Dotinurad

Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia.^[1][2] It was developed by Fuji Yakuhin and approved for use in Japan in 2020.^[2][3] The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.^[3][4]

Dotinurad

Clinical data
Trade names	Urece
Other names	FYU-981
Legal status
Legal status	Rx-only (Japan)
Identifiers
IUPAC name (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone
CAS Number	1285572-51-1
PubChem CID	51349053
DrugBank	DB16145
ChemSpider	59718651
UNII	305EB53128
KEGG	D11071
ChEMBL	ChEMBL4594446
Chemical and physical data
Formula	C14H9Cl2NO4S
Molar mass	358.19 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
InChI InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2 Key:VOFLAIHEELWYGO-UHFFFAOYSA-N

Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity by inhibiting URAT1/SLC22A12 receptor. It and epaminurad are structural analogs of Benzbromarone. ^[5][6]